CD30 Monoclonal Antibody (Ber-H2), Invitrogen™

Description

• MA5-13219 targets CD30 in IHC (P) applications and shows reactivity with Human samples
• The MA5-13219 immunogen is co cells
• CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily
• CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1
• The ligand for CD30 is CD30L (CD153)
• The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death
• CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas
• CD30 acts as a costimulatory molecule in thymic negative selection
• In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation
• In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor
• Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response
• TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB
• CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity
• Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported
• CD30 is expressed by mononuclear cells in Hodgkin's lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL)
• CD30 is also expressed by embryonal carcinomas.